Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at brentuximab for Hodgkin lymphoma (BREVITY)
This trial was for older, frail people or those with other health conditions who couldn’t have chemotherapy.
More about this trial
- find out how well treatment worked
- learn more about the side effects
Summary of results
- lymphoma went away completely (a complete metabolic response)
- lymphoma went away completely or a little bit (a complete metabolic response or a partial metabolic response)
- between 2 and 3 people out of 10 people (26%) had lymphoma that went away completely
- just over 8 out of 10 people (84%) had lymphoma that went away completely or a little bit
- 14 needed to have a lower dose due to side effects
- 11 stopped treatment altogether due to side effects
- a drop in the number of
white blood cells
- tingling or numbness in hands or feet
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor John Radford
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Birmingham
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040